AGC Biologics, a CDMO, signed a purchase agreement for Novartis’ state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, CO. The facility provides AGC with significant additional capacity and space to expand its end-to-end Cell and Gene Therapy (C&GT) offering, ensuring security of supply for current and future C&GT customers. This facility is only 16 miles from AGC’s state-of-the-art large-scale stainless steel mammalian facility in Boulder, CO.
 
This news follows an expansion at its Center of Excellence for Cell and Gene Therapy in Milan, Italy. AGC has invested heavily in C&GT services since the acquisition and integration of MolMed in 2020, and is now one of the few CDMO’s in the world offering end-to-end C&GT services, including plasmid production of all grades.
 
The Longmont facility adds 622,000 sq.-ft. of operations and office space within six buildings on the 229-acre overall campus, located 40 minutes north of Denver. AGC Biologics aims to hire a significant percentage of the talented staff employed by Novartis at the facility.
 
“The Longmont facility fits perfectly into AGC’s long-term growth and expansion plans,” said AGC Biologics Chief Executive Officer, Patricio Massera. “This move is driven by our dedication to satisfy the needs of our current and future customers.”
 
“Adding this facility into our global network will be one more step towards our vision of being able to offer our partners, whatever they need it, wherever they need it,” said AGC Biologics Chief Business Officer, Mark Womack.”